DermTech Financials

DermTech Stock Summary

DermTech competes with Q32 Bio. DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people.

DermTech Key Financial Ratios

DermTech Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining DermTech's current stock value. Our valuation model uses many indicators to compare DermTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DermTech competition to find correlations between indicators driving DermTech's intrinsic value. More Info.DermTech is rated # 3 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value DermTech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.